Table 2: NIPPV tolerability comparing younger vs. older adults.
Primary and Secondary outcomes |
Younger adults (64 or younger) N (%) |
Older adults (65 or older) N (%) |
All, N (%) |
P-Value |
Number of subjects |
41 (23) |
137 (77) |
178 |
|
Willingness to use NIPPV |
||||
Ongoing NIPPV use |
31 (76) |
75 (55) |
106 (60) |
0.02 |
Future NIPPV use |
34 (83) |
95 (70) |
129 (73) |
0.10 |
Symptom relief |
||||
Improve breathing |
37 (90) |
114 (83) |
151 (85) |
0.27 |
Improve sleep |
28 (68) |
70 (51) |
98 (55) |
0.052 |
Improve alertness |
21 (51) |
55 (40) |
76 (43) |
0.21 |
Felt better overall |
37 (90) |
100 (73) |
137 (77) |
0.02 |
Discomfort and anxiety |
||||
Mask discomfort |
17 (41) |
94 (69) |
111 (62) |
0.002 |
Worsen anxiety |
7/9 (78) |
34/44 (77) |
41/53 (77) |
0.99 |
ADL limitations |
||||
Movement limitations |
20 (49) |
62 (45) |
82 (46) |
0.69 |
Eating limitations |
26 (63) |
82 (60) |
108 (61) |
0.68 |
Talking limitations |
26 (63) |
94 (69) |
120 (67) |
0.533 |